Jove
Visualize
Contact Us

Related Concept Videos

JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
  1. Home
  3. Prognostic And Predictive Significance Of Soluble Programmed Death Ligand 1 In Bronchoalveolar Lavage Fluid In Stage Iv Non-small Cell Lung Cancer.
  1. Home
  3. Prognostic And Predictive Significance Of Soluble Programmed Death Ligand 1 In Bronchoalveolar Lavage Fluid In Stage Iv Non-small Cell Lung Cancer.

Related Experiment Video

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K

Prognostic and predictive significance of soluble programmed death ligand 1 in bronchoalveolar lavage fluid in stage

So-Yun Kim1, Dongil Park1, Pureum Sun2

  • 1Department of Internal Medicine, College of Medicine, Chungnam National University, Daejeon, Korea.

Translational Lung Cancer Research
|September 12, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

Soluble programmed death-ligand 1 (sPD-L1) in bronchoalveolar lavage fluid (BALF) can predict survival and immune checkpoint inhibitor response in stage IV non-small cell lung cancer (NSCLC) patients.

Keywords:
Non-small cell lung cancer (NSCLC)biomarkerbronchoalveolar lavage fluid (BALF)soluble programmed death-ligand 1 (sPD-L1)

More Related Videos

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.5K
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

11.1K

Related Experiment Videos

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
10:29

Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence

Published on: August 14, 2019

10.5K
Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients
07:43

Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients

Published on: September 25, 2018

10.5K
Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool
08:49

Exosomal miRNA Analysis in Non-small Cell Lung Cancer NSCLC Patients' Plasma Through qPCR: A Feasible Liquid Biopsy Tool

Published on: May 27, 2016

11.1K

Area of Science:

  • Oncology
  • Immunology
  • Pulmonology

Background:

  • Elevated soluble programmed death-ligand 1 (sPD-L1) in blood is linked to poor survival in non-small cell lung cancer (NSCLC).
  • Bronchoalveolar lavage fluid (BALF) composition reflects the lung cancer tumor microenvironment.
  • Investigating sPD-L1 in BALF for prognostic and predictive value in stage IV NSCLC.

Purpose of the Study:

  • To evaluate soluble programmed death-ligand 1 (sPD-L1) levels in bronchoalveolar lavage fluid (BALF) from stage IV NSCLC patients.
  • To determine the prognostic significance of BALF sPD-L1 for overall survival (OS).
  • To assess BALF sPD-L1 as a predictive marker for immune checkpoint inhibitor (ICI) treatment efficacy.

Main Methods:

  • Prospective collection of BALF from 94 stage IV NSCLC patients undergoing bronchoscopy (January 2020 - September 2022).
  • Quantification of sPD-L1 levels in BALF using a human PD-L1 Quantikine ELISA kit.
  • Correlation analysis with tumor cell PD-L1 expression and survival outcomes (OS, PFS), and response rates (ORR) to ICI.

    • Main Results:

    • Weakly positive correlation between tumor cell PD-L1 expression and BALF sPD-L1 (rho =0.314, P=0.002).
    • Significantly longer median overall survival (OS) in patients with low BALF sPD-L1 (16.47 months) compared to high sPD-L1 (8.87 months, P=0.001).
    • BALF sPD-L1 associated with progression-free survival (PFS) and OS in patients treated with or without ICIs.
    • Higher objective response rate (ORR) in low BALF sPD-L1 group (60.9%) versus high sPD-L1 group (12.5%, P=0.02) among ICI-treated patients.

    Conclusions:

    • Soluble PD-L1 in BALF serves as a potential prognostic indicator for stage IV NSCLC patients.
    • BALF sPD-L1 is a predictive marker for response to immune checkpoint inhibitor (ICI) therapy.
    • BALF sPD-L1 measurement offers valuable insights into tumor microenvironment and treatment outcomes.